Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
暂无分享,去创建一个
C. Held | C. Cannon | A. Siegbahn | L. Wallentin | R. Becker | C. Varenhorst | S. James | R. Storey | S. Husted | P. Steg | N. Åsenblad | J. Yčas
[1] H. Thorlacius,et al. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis , 2013, Platelets.
[2] J. Winning,et al. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock , 2013, Platelets.
[3] N. Deshpande,et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization , 2013 .
[4] G. Brandrup-Wognsen,et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. , 2013, Journal of the American College of Cardiology.
[5] P. Libby,et al. Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL Study , 2013, Journal of the American Heart Association.
[6] R. Charnigo,et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness , 2013, Journal of Thrombosis and Thrombolysis.
[7] C. Held,et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. , 2012, Journal of the American College of Cardiology.
[8] J. Sidaway,et al. Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model , 2012, Journal of cardiovascular pharmacology and therapeutics.
[9] K. Ley,et al. Regulation of Neutrophil Function by Adenosine , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[10] C. Cannon,et al. CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS , 2012 .
[11] C. Cannon,et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. , 2011, European heart journal.
[12] M. Gianni,et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation , 2011, Thrombosis and Haemostasis.
[13] S. Watson,et al. Platelets and the innate immune system: mechanisms of bacterial‐induced platelet activation , 2011, Journal of thrombosis and haemostasis : JTH.
[14] P. Pais,et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. , 2011, Journal of the American College of Cardiology.
[15] A. Nurden. Platelets, inflammation and tissue regeneration , 2011, Thrombosis and Haemostasis.
[16] C. Cannon,et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. , 2010, Journal of the American College of Cardiology.
[17] P. Gurbel,et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. , 2010, Journal of the American College of Cardiology.
[18] C. Cannon,et al. THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL , 2010 .
[19] M. Bauer,et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit* , 2010, Critical care medicine.
[20] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[21] M. Bauer,et al. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis , 2009, Journal of thrombosis and haemostasis : JTH.
[22] A. Sharrett,et al. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. , 2009, Archives of internal medicine.
[23] A. Skene,et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.
[24] D. Evans,et al. Platelet P2Y12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis , 2009, Circulation.
[25] M. Bauer,et al. Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms , 2009, Platelets.
[26] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[27] S. Balamuthusamy,et al. Hematologic Adverse Effects of Clopidogrel , 2007, American journal of therapeutics.
[28] R. Storey. Biology and pharmacology of the platelet P2Y12 receptor. , 2006, Current pharmaceutical design.
[29] K. Jacobson,et al. Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.
[30] R. Califf,et al. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). , 2006, The American journal of cardiology.
[31] R. Collins,et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.
[32] P. Ridker,et al. C-reactive protein comes of age , 2005, Nature Clinical Practice Cardiovascular Medicine.
[33] K. Reinhart,et al. Platelet and Leukocyte Activation Correlate with the Severity of Septic Organ Dysfunction , 2002, Shock.
[34] K. Ray. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. , 2002, Circulation.
[35] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[36] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .